Unique ID issued by UMIN | UMIN000007900 |
---|---|
Receipt number | R000009155 |
Scientific Title | Effect of Sitagliptin on Plaques and Cardiac Function following ACS |
Date of disclosure of the study information | 2012/05/07 |
Last modified on | 2013/11/07 14:57:50 |
Effect of Sitagliptin on Plaques and Cardiac Function following ACS
ESPECIAL-ACS
Effect of Sitagliptin on Plaques and Cardiac Function following ACS
ESPECIAL-ACS
Japan |
Acute Coronary Syndrome end Type 2 Diabetes Mellitus
Cardiology | Endocrinology and Metabolism |
Others
NO
ESPECIAL trial will evaluate the effects of DPP4 inhibitor(Sitagliptin) on
coronary plaque regression in patients with acute coronary syndrome.
The study will also assess whether the efficacy of DPP4 inhibitor also
achieve plaque stabilization and improve left ventricular function.
Efficacy
Exploratory
Pragmatic
Not applicable
percent change in coronary plaque volume
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
YES
YES
Institution is considered as adjustment factor in dynamic allocation.
NO
Central registration
2
Treatment
Medicine |
Diet+ Exercise therapy and Sitagliptin 50-100mg/day
Diet+ Exercise therapy
20 | years-old | <= |
80 | years-old | > |
Male and Female
1)Patients with Acute coronary syndrome
2)Patients with coronary plaques (≥500micro m in thickness or 20% or more in % plaque) at ≥5mm from the previously treated area in the same branch of coronary artery.
3)Patients undergoing successful percutaneous coronary intervention (PCI) under IB-IVUS guidance to culprit lesion
4)Patients eating oral diet and drug within 72 hours
5)Patients with diabetes as defined by any of the following criteria: (1) NGSP HbA1c between 6.5% and 7.4% without diabetic drug; (2) NGSP HbA1c less than 7.4% using diabetic drug
6)Patients between 20 years and 80 years old at the time of their consent.
7)Patients giving written consent by their own volition after being provided sufficient explanation for participation in this clinical trial.
1)diseased bypass graft
2)Patients who have plaque in a non-culprit site on the PCI vessel and might undergo PCI during the treatment period.
3)Patients receiving DPP4 inhibitor drugs and GLP-1 and high dose SU drugs at admission
4)Patients receiving more than 3 anti-diabetic drugs
5)Patients with acute congestive heart failure
6)Patients with ketoacidosis and diabetic coma within 6 months
7)Severe infection, Pre-operative and post-operative state, and severe trauma
8)Pregnant women, women suspected of being pregnant, or lactating women
9)Patients with severe renal disorders or undergoing dialysis
10)Patients with active malignant tumor
11)Patients with any allergy to DPP4 inhibitor
12)Patients who are ineligible in the opinion of the investigator.
46
1st name | |
Middle name | |
Last name | Hiroyuki Daida |
Juntendo University
Cardiovascular Medicine
2-1-1 Hongo Bunkyo-ku Tokyo
03-3813-3111
ktmmy@juntendo.ac.jp
1st name | |
Middle name | |
Last name | Katsumi Miyauchi |
Juntendo University
Cardiovascular Medicine
2-1-1 Bunkyo-ku Hongo,Tokyo
03-3813-3111
ktmmy@juntendo.ac.jp
ESPECIAL-ACS office
The Kidney Foundation, Japan
Non profit foundation
NO
2012 | Year | 05 | Month | 07 | Day |
Unpublished
Open public recruiting
2012 | Year | 03 | Month | 09 | Day |
2012 | Year | 05 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2014 | Year | 03 | Month | 01 | Day |
2014 | Year | 03 | Month | 01 | Day |
2014 | Year | 06 | Month | 01 | Day |
2012 | Year | 05 | Month | 07 | Day |
2013 | Year | 11 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009155